US Broker Ratings

Talkspace, Inc. (TALK) Investor Outlook: A Healthcare Disruptor with 34.92% Potential Upside

Talkspace, Inc. (NASDAQ: TALK) is making waves in the healthcare sector with its innovative approach to mental health services. As a virtual behavioral healthcare company, Talkspace..

AbCellera Biologics Inc. (ABCL) Stock Report: Exploring a Potential 178% Upside

AbCellera Biologics Inc. (NASDAQ: ABCL), a key player in the biotechnology sector, has caught the attention of investors with its promising potential upside of 178.56%. As..

Keros Therapeutics, Inc. (KROS) Investor Outlook: A 16% Upside Potential with Robust Revenue Growth

Keros Therapeutics, Inc. (NASDAQ: KROS), a burgeoning player in the biotechnology sector, has been capturing investor attention with its impressive revenue growth and promising pipeline of..

Replimune Group, Inc. (REPL) Stock Analysis: Unveiling the 29.74% Potential Upside in Biotech

Replimune Group, Inc. (NASDAQ: REPL) is emerging as a compelling player in the biotechnology sector, capturing investor attention with its innovative approach to cancer treatment through..

Cogent Biosciences, Inc. (COGT) Stock Analysis: A Biotech Gem with 29% Upside Potential

Investors with a keen eye on the biotechnology sector may find Cogent Biosciences, Inc. (NASDAQ: COGT) particularly intriguing. With a market capitalization of $5.82 billion, the..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Navigating a 55.66% Potential Upside in Biotech

For investors with an eye on the biotechnology sector, Praxis Precision Medicines, Inc (NASDAQ: PRAX) presents an intriguing opportunity. With a market capitalization of $6.73 billion,..

KalVista Pharmaceuticals, Inc. (KALV): Analyst Consensus Reveals Over 100% Potential Upside

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a burgeoning name in the biotechnology sector, is capturing investor attention with its innovative approach to addressing unmet medical needs. Specializing..

Bicycle Therapeutics plc (BCYC) Stock Analysis: Exploring a 217.58% Potential Upside

Bicycle Therapeutics plc (BCYC), a UK-based biotechnology firm, is making waves in the healthcare sector with its innovative therapeutic solutions aimed at addressing diseases lacking effective..

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a 239% Upside Potential in Innovative Cancer Therapies

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a company at the forefront of biotechnology, is capturing the attention of investors with its promising therapies targeting metastatic melanoma and..

Eton Pharmaceuticals (ETON) Investor Outlook: Exploring an 87% Potential Upside in the Rare Disease Market

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is capturing investor attention with its robust growth potential in the niche market of rare disease treatments. With a market capitalization..

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Unpacking the 84.65% Potential Upside for Investors

In the ever-evolving landscape of biotechnology, Bicara Therapeutics Inc. (NASDAQ: BCAX) emerges as a compelling player with substantial growth potential. With a market capitalization of $966.35..

GH Research PLC (GHRS) Stock Analysis: Exploring a 138.80% Upside in the Biotech Sector

GH Research PLC (NASDAQ: GHRS), a Dublin-based biopharmaceutical company, is making waves in the healthcare sector with its innovative approach to treating depression. The company’s focus..

Xencor, Inc. (XNCR) Investor Outlook: An 80% Upside Potential in the Biotech Frontier

Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company based in Pasadena, California, is capturing the attention of investors with a potential upside of 80.05%, according to current..

Pharvaris N.V. (PHVS) Stock Analysis: Potential Upside of Over 90% Beckons Investors

Pharvaris N.V. (PHVS), a biopharmaceutical entity based in Zug, Switzerland, is making waves in the healthcare sector with its pioneering approach to treating rare diseases such..

Sionna Therapeutics, Inc. (SION) Stock Analysis: Strong Buy Ratings Amidst Promising Cystic Fibrosis Pipeline

Sionna Therapeutics, Inc. (SION), a burgeoning player in the biotechnology sector, has captured the attention of investors with its promising pipeline focused on cystic fibrosis treatments...

Embecta Corp. (EMBC) Stock Analysis: Exploring a 42% Potential Upside in the Healthcare Sector

Embecta Corp. (NASDAQ: EMBC), a prominent player in the healthcare sector, specializes in medical instruments and supplies, focusing on diabetes management solutions. Despite operating in a..

SI-BONE, Inc. (SIBN) Stock Analysis: A Robust 27.85% Potential Upside Beckons Investors

SI-BONE, Inc. (NASDAQ: SIBN) is making waves in the healthcare sector, specifically within the medical devices industry, with a strong focus on innovative solutions for musculoskeletal..

Arcus Biosciences, Inc. (RCUS) Stock Analysis: Unveiling a 45.98% Upside Potential Amidst Clinical Innovations

Arcus Biosciences, Inc. (NASDAQ: RCUS), a trailblazer in the biotechnology sector, holds a promising position in the healthcare industry with a market capitalization of $2.72 billion...

RxSight, Inc. (RXST) Stock Analysis: Navigating a -16.06% Potential Downside with Innovative Technology

RxSight, Inc. (NASDAQ: RXST), a prominent player in the healthcare sector, specifically within the medical devices industry, is attracting attention due to its innovative approach to..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Strong Revenue Growth and Promising Analyst Ratings

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) has been making waves in the healthcare sector, particularly within the drug manufacturing industry specializing in both specialty and generic formulations...

US Broker Ratings

US Broker Ratings

FTSE 100

Funds